Pfizer's stock rose 0.48% in its latest trading session, outperforming the S&P 500's 0.13% uptick, while other indices ...

Pfizer (PFE) investors are bound to be disappointed with the stock’s price action. With a year-to-date loss of 16.7% as of ...

In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...

Best of all, shares of the company are historically cheap and producing a jaw-dropping annual yield. Investors can pick up ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

The stock's fall snapped a three-day winning streak.

Pfizer just pulled the plug on its oral weight-loss pill danuglipron after a liver injury case raised safety alarms. This decision underscores how the path from lab to medicine cabinet is riddled with ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...